Cutting Gel claims false and unsubstantiated...

The Federal Trade Commission has charged the makers of cutting gel with making numerous false and unsubstantiated claims their products.

The complaint focuses on six of the respondents’ heavily promoted products, including Dermalin, Cutting Gel, and Tummy Flattening Gel, Leptoprin and Anorex, and PediaLean.

The Federal Trade Commission alleges that the company made unsubstantiated fat and weight loss claims, false claims that clinical testing proves certain efficacy claims, and false claims that Daniel B. Mowrey, Ph.D, is a medical doctor.

Dermalin, Cutting Gel, and Tummy Flattening Gel all contain the active ingredient aminophylline in a lecithin base. Dermalin and Tummy Flattening Gel are sold under the Klein-Becker USA and Sovage trade names, and are advertised primarily to women interested in thinning their figures.

Cutting Gel, sold under the Nutrasport trade name, is primarily advertised to male bodybuilders who want to eliminate areas of fat that obscure muscle definition.

The complaint challenges as unsubstantiated claims that Dermalin, Cutting Gel, and Tummy Flattening Gel cause rapid and visibly obvious fat loss in areas of the body to which they are applied.

The complaint challenges as false the claim that published, clinical testing proves that Cutting Gel and Tummy Flattening Gel cause rapid and visibly obvious fat loss in areas of the body to which they are applied.

The complaint further challenges as unsubstantiated claims that Leptoprin and Anorex cause weight loss of more than 20 pounds in significantly overweight users and that those products cause loss of substantial, excess fat in significantly overweight users.

In addition, the complaint challenges as false claims that clinical testing proves that Leptoprin causes weight loss of more than 20 pounds, including as much as 50, 60, or 147 pounds, in significantly overweight users; and that clinical testing proves that Leptoprin causes loss of substantial, excess fat in significantly overweight users.

In addition, the complaint challenges claims that PediaLean causes substantial weight loss in overweight or obese children, and that clinical testing proves such claims. The complaint further challenges the respondents’ claim that respondent Mowrey is a medical doctor. The Federal Trade Commission alleges that he is not.

Related Articles

• Belly Fat and How to Beat It
• How to Fight Fat and Win (Members Only)
• The Maximum Muscle Plan (Members Only)
• The Myth about Muscle and Your Metabolic Rate

Reference
Federal Trade Commission File No. 002-3300
http://www.ftc.gov/opa/2004/06/dietsupp.htm